The Novel Soluble Guanylate Cyclase Stimulator Attenuates Acute Lung Injury via Inhibiting Pericyte Phenotypic Transition
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031346 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yu-Long Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. Hauptthemen laut MEDLINE: Soluble Guanylyl Cyclase, Acute Lung Injury, Pericytes, Enzyme Activators. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute lung injury (ALI) pathogenesis is intricately linked to microvascular permeability. Soluble guanylate cyclase (sGC) is prominently expressed in the vascular system, playing a central role in vascular function. In contrast, its expression and function diminish notably during the progression of ALI, indicating sGC’s potential significance as a pivotal modulator in the pathological processes of ALI. Nonetheless, the precise localization of sGC within lung tissue and its distinct mechanism in maintaining vascular homeostasis remain unclear. Furthermore, there is a necessity for a pharmacological agent capable of consistently activating sGC for the treatment of ALI. A novel sGC stimulator, sGC003, was engineered through structural modification of Riociguat. In a mouse model of ALI, sGC003 exhibited superior sGC activation and more potent anti-inflammatory effects relative to Riociguat. It also exhibited superior efficacy in improving respiratory function and reducing pulmonary edema. Through single-cell RNA sequencing and immunofluorescence co-localization analysis, we confirmed predominant expression of soluble guanylate cyclase in pericytes. The sGC stimulators were found to modulate the LPS-induced pericyte transcriptome reprogramming via the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway. Differential gene expression analysis categorized pericytes into nine distinct subgroups, which were sequentially activated during vascular development, inflammation, and myofibrosis. Pseudotime analysis revealed that sGC003 more effectively suppressed the myofibroblast differentiation of pericytes compared to Riociguat. In conclusion, sGC003 mitigates ALI-induced pulmonary inflammation by modulating pericyte differentiation, particularly in preserving microvascular integrity outstanding performance. Its exceptional efficacy suggests that it could potentially serve as a safer and more efficient option as a novel sGC stimulant in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
- School of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
ORCID-Profile: Xia Li, Jin-Shui Zhang, You-Zhi Zhang
Zitieren
APA
Huang, Y. L., Li, S., Li, X., Zhang, J. S., Shi, Y. X., Su, G. X., Zhang, Y., Xue, R., Li, J. C., Fan, Q. Y., Zheng, Z. B., Deng, Y., & Zhang, Y. Z. (2026). The Novel Soluble Guanylate Cyclase Stimulator Attenuates Acute Lung Injury via Inhibiting Pericyte Phenotypic Transition. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031346
Vancouver
Huang YL, Li S, Li X, Zhang JS, Shi YX, Su GX, et al. The Novel Soluble Guanylate Cyclase Stimulator Attenuates Acute Lung Injury via Inhibiting Pericyte Phenotypic Transition. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031346
BibTeX
@article{Huang2026,
author = {Huang, Yu-Long and Li, Shuo and Li, Xia and Zhang, Jin-Shui and Shi, Ying-Xian and Su, Gui-Xin and Zhang, Yang and Xue, Rui and Li, Jing-Cao and Fan, Qiong-Yin and Zheng, Zhi-Bing and Deng, Yun and Zhang, You-Zhi},
title = {The Novel Soluble Guanylate Cyclase Stimulator Attenuates Acute Lung Injury via Inhibiting Pericyte Phenotypic Transition},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031346}
}
EUVIMED